Revenue, R&D budgets and M&A activity in the biotech sector were up in 2011, according to Ernst & Young’s annual market evaluation. Venture capital remained essentially flat, but E&Y life science leader Glen Giovannetti told FierceBiotech that the flow of investment cash into the sector will likely drop in 2013-2014.
Infinity Pharmaceuticals was downgraded to overweight at Piper Jaffray after announcing it is halting a phase 2 trial for its lead drug saridegib for bone and cartilage cancers. Earlier this year, Infinity pulled the plug on a study on a mid-stage trial for the drug in pancreatic cancer.
“The oncology cost curve is unsustainable,” Rhonda Greenapple, chief executive of Reimbursement Intelligence, told Reuters. “Affordability is more of an issue in therapy selection.” The good news, the article says, is that although the cost of targeted cancer meds is soaring, new research suggests that cheaper generics may work just as well as branded cancer drugs.
Children are taking fewer antibiotics and prescription drugs in general than they were ten years ago. But here’s what they’re taking more of: contraceptives and drugs for attention deficit hyperactivity disorder.
During the China Day program at 2012 BIO International Convention, David W. Beier, senior vice president at Amgen and former chief domestic policy advisor to Vice President Al Gore, offered key points to helping biotech flourish in China.
Doctors feel so strong an obligation to colleagues and patients that they go to work when they’re sick sometimes, just like most of the rest of us. A team of researchers from Massachusetts General Hospital surveyed 150 doctors and found that more than half of them have worked with flu symptoms in the past year. Admirable or risky?
[Photo Credit: jannoon028]